[J01EC01, sulfamethoxazole, Lenvatinib may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[M04AB02, sulfinpyrazone, Lenvatinib may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level.]
[S01AB02, sulfisoxazole, The risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Lenvatinib.]
[N05AL01, sulpiride, The risk or severity of QTc prolongation can be increased when Sulpiride is combined with Lenvatinib.]
[L01BB02, mercaptopurine, The excretion of Mercaptopurine can be decreased when combined with Lenvatinib.]
[L02BA01, tamoxifen, The serum concentration of Lenvatinib can be increased when it is combined with Tamoxifen.]
[R03CC03, terbutaline, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Lenvatinib.]
[B01AE07, dabigatran etexilate, The serum concentration of Lenvatinib can be increased when it is combined with Dabigatran etexilate.]
[N07XX06, tetrabenazine, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Tetrabenazine.]
[S01HA03, tetracaine, The risk or severity of methemoglobinemia can be increased when Lenvatinib is combined with Tetracaine.]
[S03AA02, tetracycline, The excretion of Tetracycline can be decreased when combined with Lenvatinib.]
[N05AE05, lurasidone, The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Lenvatinib.]
[N04BC07, apomorphine, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Lenvatinib.]
[L01XX41, eribulin, The risk or severity of QTc prolongation can be increased when Eribulin is combined with Lenvatinib.]
[N05AC02, thioridazine, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Thioridazine.]
[N05AF04, thiothixene, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Lenvatinib.]
[V04CJ01, thyrotropin, The therapeutic efficacy of Thyrotropin can be decreased when used in combination with Lenvatinib.]
[V04CJ02, thyrotropin-releasing hormone, The therapeutic efficacy of Protirelin can be decreased when used in combination with Lenvatinib.]
[S01ED01, timolol, The risk or severity of QTc prolongation can be increased when Timolol is combined with Lenvatinib.]
[P01AB02, tinidazole, Lenvatinib may decrease the excretion rate of Tinidazole which could result in a higher serum level.]
[N06AX05, trazodone, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Lenvatinib.]
[S01AD02, trifluridine, The excretion of Trifluridine can be decreased when combined with Lenvatinib.]
[A03AA05, trimebutine, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Lenvatinib.]
[R06AD01, trimeprazine, The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Lenvatinib.]
[N03AC02, trimethadione, The risk or severity of QTc prolongation can be increased when Trimethadione is combined with Lenvatinib.]
[N06AA06, trimipramine, The serum concentration of Trimipramine can be increased when it is combined with Lenvatinib.]
[R06AX07, triprolidine, The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Lenvatinib.]
[L01EX04, vandetanib, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Vandetanib.]
[A10BH05, linagliptin, The serum concentration of Lenvatinib can be increased when it is combined with Linagliptin.]
[J05AP02, telaprevir, The serum concentration of Lenvatinib can be increased when it is combined with Telaprevir.]
[J05AG05, rilpivirine, Rilpivirine may decrease the excretion rate of Lenvatinib which could result in a higher serum level.]
[N03AX21, ezogabine, The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Lenvatinib.]
[B01AF01, rivaroxaban, The serum concentration of Lenvatinib can be increased when it is combined with Rivaroxaban.]
[R03AC18, indacaterol, The serum concentration of Lenvatinib can be increased when it is combined with Indacaterol.]
[B01AC24, ticagrelor, The serum concentration of Lenvatinib can be increased when it is combined with Ticagrelor.]
[C08DA01, verapamil, The serum concentration of Lenvatinib can be increased when it is combined with Verapamil.]
[L01CA01, vinblastine, Lenvatinib may decrease the excretion rate of Vinblastine which could result in a higher serum level.]
[L01CA02, vincristine, Lenvatinib may decrease the excretion rate of Vincristine which could result in a higher serum level.]
[J05AF01, zidovudine, The excretion of Zidovudine can be decreased when combined with Lenvatinib.]
[N05AF05, zuclopenthixol, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Zuclopenthixol.]
[J05AE02, indinavir, Lenvatinib may decrease the excretion rate of Indinavir which could result in a higher serum level.]
[L01EC01, vemurafenib, The serum concentration of Lenvatinib can be increased when it is combined with Vemurafenib.]
[L01FX05, brentuximab vedotin, The serum concentration of Brentuximab vedotin can be increased when it is combined with Lenvatinib.]
[L01ED01, crizotinib, The risk or severity of QTc prolongation can be increased when Crizotinib is combined with Lenvatinib.]
[A02BC04, rabeprazole, Rabeprazole may decrease the excretion rate of Lenvatinib which could result in a higher serum level.]
[M05BA06, ibandronic acid, The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Lenvatinib.]
[J01MA13, trovafloxacin, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Trovafloxacin.]
[N05AE04, ziprasidone, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Ziprasidone.]
[G04BD07, tolterodine, The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Lenvatinib.]
[J01DH04, doripenem, The excretion of Doripenem can be decreased when combined with Lenvatinib.]
[C07AB03, atenolol, Lenvatinib may decrease the excretion rate of Atenolol which could result in a higher serum level.]
[J02AC03, voriconazole, The serum concentration of Lenvatinib can be increased when it is combined with Voriconazole.]
[S01FA01, atropine, Lenvatinib may decrease the excretion rate of Atropine which could result in a higher serum level.]
[L01XJ01, vismodegib, Vismodegib may decrease the excretion rate of Lenvatinib which could result in a higher serum level.]
[L01EK01, axitinib, The serum concentration of Axitinib can be increased when it is combined with Lenvatinib.]
[R07AX02, ivacaftor, The serum concentration of Lenvatinib can be increased when it is combined with Ivacaftor.]
[B03XA04, peginesatide, The risk or severity of Thrombosis can be increased when Peginesatide is combined with Lenvatinib.]
[L01BC05, gemcitabine, The serum concentration of Gemcitabine can be increased when it is combined with Lenvatinib.]
[G04BE10, avanafil, Avanafil may decrease the excretion rate of Lenvatinib which could result in a higher serum level.]
[G04BD12, mirabegron, The serum concentration of Lenvatinib can be increased when it is combined with Mirabegron.]
[L01XG02, carfilzomib, The serum concentration of Lenvatinib can be increased when it is combined with Carfilzomib.]
[V03AX03, cobicistat, Cobicistat may decrease the excretion rate of Lenvatinib which could result in a higher serum level.]
[L01EA04, bosutinib, The serum concentration of Bosutinib can be increased when it is combined with Lenvatinib.]
[L04AA31, teriflunomide, Teriflunomide may decrease the excretion rate of Lenvatinib which could result in a higher serum level.]
[L01EX05, regorafenib, Regorafenib may decrease the excretion rate of Lenvatinib which could result in a higher serum level.]
[J05AE04, nelfinavir, Lenvatinib may decrease the excretion rate of Nelfinavir which could result in a higher serum level.]
[L01AA09, bendamustine, The serum concentration of Bendamustine can be increased when it is combined with Lenvatinib.]
[H01CB05, pasireotide, The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Lenvatinib.]
[G04BE03, sildenafil, The serum concentration of Lenvatinib can be increased when it is combined with Sildenafil.]
[L01EA05, ponatinib, Ponatinib may decrease the excretion rate of Lenvatinib which could result in a higher serum level.]
[B01AF02, apixaban, The serum concentration of Lenvatinib can be increased when it is combined with Apixaban.]
[C10AX12, lomitapide, The serum concentration of Lenvatinib can be increased when it is combined with Lomitapide.]
[J04AK05, bedaquiline, The risk or severity of QTc prolongation can be increased when Bedaquiline is combined with Lenvatinib.]
[C04AX11, bencyclane, The risk or severity of QTc prolongation can be increased when Bencyclane is combined with Lenvatinib.]
[L04AX06, pomalidomide, The serum concentration of Pomalidomide can be increased when it is combined with Lenvatinib.]
[A10BK02, canagliflozin, The serum concentration of Lenvatinib can be increased when it is combined with Canagliflozin.]
[J01MA15, gemifloxacin, The risk or severity of QTc prolongation can be increased when Gemifloxacin is combined with Lenvatinib.]
[M04AB03, benzbromarone, Lenvatinib may decrease the excretion rate of Benzbromarone which could result in a higher serum level.]
[S01AE07, moxifloxacin, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Lenvatinib.]
[A06AX06, tegaserod, The serum concentration of Lenvatinib can be increased when it is combined with Tegaserod.]
[H03AA04, tiratricol, The therapeutic efficacy of Tiratricol can be decreased when used in combination with Lenvatinib.]
[R02AD01, benzocaine, The risk or severity of methemoglobinemia can be increased when Lenvatinib is combined with Benzocaine.]
[J02AX04, caspofungin, The excretion of Caspofungin can be decreased when combined with Lenvatinib.]
[M01AH01, celecoxib, The risk or severity of liver damage can be increased when Celecoxib is combined with Lenvatinib.]
[L04AA18, everolimus, The serum concentration of Lenvatinib can be increased when it is combined with Everolimus.]
[N04AC01, benztropine, The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Lenvatinib.]
[L01EC02, dabrafenib, Dabrafenib may decrease the excretion rate of Lenvatinib which could result in a higher serum level.]
[P03AX06, benzyl alcohol, The risk or severity of methemoglobinemia can be increased when Lenvatinib is combined with Benzyl alcohol.]
[H05AA03, parathyroid hormone, The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Lenvatinib.]
[L01EB03, afatinib, Afatinib may decrease the excretion rate of Lenvatinib which could result in a higher serum level.]
[J05AJ03, dolutegravir, The serum concentration of Lenvatinib can be increased when it is combined with Dolutegravir.]
[C08EA02, bepridil, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Bepridil.]
[C02KX05, riociguat, The serum concentration of Lenvatinib can be increased when it is combined with Riociguat.]
[A05AA03, cholic acid, Lenvatinib may decrease the excretion rate of Cholic Acid which could result in a higher serum level.]
[J05AP05, simeprevir, Simeprevir may decrease the excretion rate of Lenvatinib which could result in a higher serum level.]
[J05AP08, sofosbuvir, The serum concentration of Lenvatinib can be increased when it is combined with Sofosbuvir.]
[L01ED02, ceritinib, The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Lenvatinib.]
[B01AC26, vorapaxar, The serum concentration of Lenvatinib can be increased when it is combined with Vorapaxar.]
[A03BA03, hyoscyamine, The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Lenvatinib.]
[L01XH04, belinostat, The serum concentration of Lenvatinib can be increased when it is combined with Belinostat.]
[L01EM01, idelalisib, The serum concentration of Lenvatinib can be increased when it is combined with Idelalisib.]
[N07XX08, tafamidis, The serum concentration of Lenvatinib can be increased when it is combined with Tafamidis.]
[R03AC19, olodaterol, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Lenvatinib.]
[N05CM19, suvorexant, The serum concentration of Lenvatinib can be increased when it is combined with Suvorexant.]
[A16AX10, eliglustat, The serum concentration of Lenvatinib can be increased when it is combined with Eliglustat.]
[L01EX09, nintedanib, The serum concentration of Nintedanib can be increased when it is combined with Lenvatinib.]
[S03AA06, gentamicin, The serum concentration of Gentamicin can be increased when it is combined with Lenvatinib.]
[J05AP09, dasabuvir, Dasabuvir may decrease the excretion rate of Lenvatinib which could result in a higher serum level.]
[B01AF03, edoxaban, The serum concentration of Lenvatinib can be increased when it is combined with Edoxaban.]
[N06AX11, mirtazapine, The risk or severity of QTc prolongation can be increased when Mirtazapine is combined with Lenvatinib.]
[L01EF01, palbociclib, Palbociclib may decrease the excretion rate of Lenvatinib which could result in a higher serum level.]
[S01AA13, fusidic acid, Fusidic acid may decrease the excretion rate of Lenvatinib which could result in a higher serum level.]
[J01MB04, pipemidic acid, The risk or severity of QTc prolongation can be increased when Pipemidic acid is combined with Lenvatinib.]
[L01XH03, panobinostat, The risk or severity of QTc prolongation can be increased when Panobinostat is combined with Lenvatinib.]
[J05AP07, daclatasvir, Daclatasvir may decrease the excretion rate of Lenvatinib which could result in a higher serum level.]
[N02BE01, acetaminophen, The serum concentration of Acetaminophen can be increased when it is combined with Lenvatinib.]
[C01EB17, ivabradine, Ivabradine may increase the QTc-prolonging activities of Lenvatinib.]
[J05AP06, asunaprevir, The serum concentration of Lenvatinib can be increased when it is combined with Asunaprevir.]
[A07DA06, eluxadoline, The serum concentration of Eluxadoline can be increased when it is combined with Lenvatinib.]
[A04AD14, rolapitant, Rolapitant may decrease the excretion rate of Lenvatinib which could result in a higher serum level.]
[G02CX02, flibanserin, The serum concentration of Lenvatinib can be increased when it is combined with Flibanserin.]
[A02BC03, lansoprazole, Lansoprazole may decrease the excretion rate of Lenvatinib which could result in a higher serum level.]
[J02AC05, isavuconazole, The serum concentration of Lenvatinib can be increased when it is combined with Isavuconazole.]
[L01EB04, osimertinib, Osimertinib may decrease the excretion rate of Lenvatinib which could result in a higher serum level.]
[J05AF13, tenofovir alafenamide, The excretion of Tenofovir alafenamide can be decreased when combined with Lenvatinib.]
[L01EE02, cobimetinib, The serum concentration of Cobimetinib can be increased when it is combined with Lenvatinib.]
[L01ED03, alectinib, Alectinib may decrease the excretion rate of Lenvatinib which could result in a higher serum level.]
[B01AC27, selexipag, The serum concentration of Selexipag can be increased when it is combined with Lenvatinib.]
[G04CA01, alfuzosin, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Lenvatinib.]
[J05AP10, elbasvir, Elbasvir may decrease the excretion rate of Lenvatinib which could result in a higher serum level.]
[J05AP11, grazoprevir, Grazoprevir may decrease the excretion rate of Lenvatinib which could result in a higher serum level.]
[L01XX52, venetoclax, Venetoclax may decrease the excretion rate of Lenvatinib which could result in a higher serum level.]
[R06AB01, brompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Lenvatinib.]
[A05AA04, obeticholic acid, The risk or severity of adverse effects can be increased when Lenvatinib is combined with Obeticholic acid.]
[C03CA02, bumetanide, The excretion of Bumetanide can be decreased when combined with Lenvatinib.]
[N01BB01, bupivacaine, The risk or severity of methemoglobinemia can be increased when Lenvatinib is combined with Bupivacaine.]
[C07AA19, bupranolol, The risk or severity of QTc prolongation can be increased when Bupranolol is combined with Lenvatinib.]
[N07BC01, buprenorphine, Buprenorphine may decrease the excretion rate of Lenvatinib which could result in a higher serum level.]
[L02AE01, buserelin, The risk or severity of QTc prolongation can be increased when Buserelin is combined with Lenvatinib.]
[L01XX27, arsenic trioxide, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Arsenic trioxide.]
[P01BE02, artemether, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Artemether.]
[M02AA03, clofezone, Rabeprazole may decrease the excretion rate of Lenvatinib which could result in a higher serum level.]
[J01MA09, sparfloxacin, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Sparfloxacin.]
[R06AX09, azatadine, The risk or severity of QTc prolongation can be increased when Azatadine is combined with Lenvatinib.]
[L01XK03, rucaparib, Rucaparib may decrease the excretion rate of Lenvatinib which could result in a higher serum level.]
[S01AA26, azithromycin, The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Lenvatinib.]
[L01EF02, ribociclib, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Ribociclib.]
[N07XX16, deutetrabenazine, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Deutetrabenazine.]
[N02BF02, pregabalin, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Lenvatinib.]
[N06BC01, caffeine, Caffeine may decrease the excretion rate of Lenvatinib which could result in a higher serum level.]
[S01HA02, benoxinate, The risk or severity of methemoglobinemia can be increased when Lenvatinib is combined with Oxybuprocaine.]
[J05AE09, tipranavir, Lenvatinib may decrease the excretion rate of Tipranavir which could result in a higher serum level.]
[H03BA03, benzylthiouracil, The therapeutic efficacy of Benzylthiouracil can be decreased when used in combination with Lenvatinib.]
[H05AA04, abaloparatide, The therapeutic efficacy of Abaloparatide can be decreased when used in combination with Lenvatinib.]
[L01ED04, brigatinib, Brigatinib may decrease the excretion rate of Lenvatinib which could result in a higher serum level.]
[N04BD03, safinamide, Safinamide may decrease the excretion rate of Lenvatinib which could result in a higher serum level.]
[J01MA23, delafloxacin, The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Lenvatinib.]
[B01AF04, betrixaban, The serum concentration of Betrixaban can be increased when it is combined with Lenvatinib.]
[L01XX59, enasidenib, Enasidenib may decrease the excretion rate of Lenvatinib which could result in a higher serum level.]
[L01EH02, neratinib, The serum concentration of Lenvatinib can be increased when it is combined with Neratinib.]
[L01FB01, inotuzumab ozogamicin, The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Lenvatinib.]
[L01XH01, vorinostat, The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Lenvatinib.]
[L01EM02, copanlisib, The serum concentration of Copanlisib can be increased when it is combined with Lenvatinib.]
[L01EF03, abemaciclib, Abemaciclib may decrease the excretion rate of Lenvatinib which could result in a higher serum level.]
[C07AB07, bisoprolol, The serum concentration of Lenvatinib can be increased when it is combined with Bisoprolol.]
[J05AG03, efavirenz, Lenvatinib may decrease the excretion rate of Efavirenz which could result in a higher serum level.]
[R03BA02, budesonide, Lenvatinib may decrease the excretion rate of Budesonide which could result in a higher serum level.]
[J05AX18, letermovir, Letermovir may decrease the excretion rate of Lenvatinib which could result in a higher serum level.]
[N06AA15, butriptyline, The risk or severity of QTc prolongation can be increased when Butriptyline is combined with Lenvatinib.]
[C01AA02, acetyldigoxins, The risk or severity of QTc prolongation can be increased when Acetyldigoxin is combined with Lenvatinib.]
[N01BX04, capsaicin, The risk or severity of methemoglobinemia can be increased when Lenvatinib is combined with Capsaicin.]
[A10BK04, ertugliflozin, The serum concentration of Ertugliflozin can be increased when it is combined with Lenvatinib.]
[R06AX18, acrivastine, The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Lenvatinib.]
[C09AA01, captopril, The excretion of Captopril can be decreased when combined with Lenvatinib.]
[V04CD06, macimorelin, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Macimorelin.]
[L02BB05, apalutamide, The serum concentration of Lenvatinib can be decreased when it is combined with Apalutamide.]
[H03BB01, carbimazole, The therapeutic efficacy of Carbimazole can be decreased when used in combination with Lenvatinib.]
[R06AA08, carbinoxamine, The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Lenvatinib.]
[C07AG02, carvedilol, The serum concentration of Lenvatinib can be increased when it is combined with Carvedilol.]
[B02BX09, fostamatinib, Fostamatinib may decrease the excretion rate of Lenvatinib which could result in a higher serum level.]
[N03AX24, cannabidiol, Cannabidiol may decrease the excretion rate of Lenvatinib which could result in a higher serum level.]
[B02BX08, avatrombopag, Avatrombopag may decrease the excretion rate of Lenvatinib which could result in a higher serum level.]
[L04AA37, baricitinib, The serum concentration of Baricitinib can be increased when it is combined with Lenvatinib.]
[L01EC03, encorafenib, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Encorafenib.]
[L01EE03, binimetinib, The serum concentration of Binimetinib can be increased when it is combined with Lenvatinib.]
[J01DD14, ceftibuten, The excretion of Ceftibuten can be decreased when combined with Lenvatinib.]
[C07AB08, celiprolol, The risk or severity of QTc prolongation can be increased when Celiprolol is combined with Lenvatinib.]
[H01CC03, elagolix, The serum concentration of Lenvatinib can be increased when it is combined with Elagolix.]
[L01XX62, ivosidenib, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Ivosidenib.]
[N03AX17, stiripentol, The excretion of Lenvatinib can be decreased when combined with Stiripentol.]
[B02BX07, lusutrombopag, The serum concentration of Lusutrombopag can be increased when it is combined with Lenvatinib.]
[L01EM04, duvelisib, The serum concentration of Duvelisib can be increased when it is combined with Lenvatinib.]
[L01EB07, dacomitinib, Dacomitinib may decrease the excretion rate of Lenvatinib which could result in a higher serum level.]
[J01AA14, sarecycline, The serum concentration of Lenvatinib can be increased when it is combined with Sarecycline.]
[J01AA15, omadacycline, The serum concentration of Omadacycline can be increased when it is combined with Lenvatinib.]
[S01GX12, cetirizine, The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Lenvatinib.]
[N01BA04, chloroprocaine, The risk or severity of methemoglobinemia can be increased when Lenvatinib is combined with Chloroprocaine.]
[N07XX15, inotersen, The risk or severity of QTc prolongation can be increased when Inotersen is combined with Lenvatinib.]
[L01XK04, talazoparib, The serum concentration of Talazoparib can be increased when it is combined with Lenvatinib.]
[R03BB08, revefenacin, Lenvatinib may decrease the excretion rate of Revefenacin which could result in a higher serum level.]
[L01EX12, larotrectinib, The serum concentration of Larotrectinib can be increased when it is combined with Lenvatinib.]
[L01EX13, gilteritinib, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Gilteritinib.]
[L01XJ03, glasdegib, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Glasdegib.]
[N07XX05, amifampridine, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Amifampridine.]
[C01BG07, cifenline, The risk or severity of QTc prolongation can be increased when Cibenzoline is combined with Lenvatinib.]
[B01AC23, cilostazol, The risk or severity of QTc prolongation can be increased when Cilostazol is combined with Lenvatinib.]
[P02BX04, triclabendazole, The risk or severity of QTc prolongation can be increased when Triclabendazole is combined with Lenvatinib.]
[J01FA09, clarithromycin, Lenvatinib may decrease the excretion rate of Clarithromycin which could result in a higher serum level.]
[N06BA14, solriamfetol, The serum concentration of Solriamfetol can be increased when it is combined with Lenvatinib.]
[L01EN01, erdafitinib, The serum concentration of Lenvatinib can be increased when it is combined with Erdafitinib.]
[N05BA09, clobazam, The serum concentration of Lenvatinib can be increased when it is combined with Clobazam.]
[J01DC04, cefaclor, Lenvatinib may decrease the excretion rate of Cefaclor which could result in a higher serum level.]
[J01DB04, cefazolin, The excretion of Cefazolin can be decreased when combined with Lenvatinib.]
[L02BB06, darolutamide, The serum concentration of Lenvatinib can be increased when it is combined with Darolutamide.]
[J01DC07, cefotiam, The excretion of Cefotiam can be decreased when combined with Lenvatinib.]
[C03BX03, cicletanine, The risk or severity of QTc prolongation can be increased when Cicletanine is combined with Lenvatinib.]
[J01DD07, ceftizoxime, The excretion of Ceftizoxime can be decreased when combined with Lenvatinib.]
[L01EJ02, fedratinib, Fedratinib may decrease the excretion rate of Lenvatinib which could result in a higher serum level.]
[L01EX14, entrectinib, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Entrectinib.]
[N07XX11, pitolisant, Lenvatinib may increase the QTc-prolonging activities of Pitolisant.]
[J01XX12, lefamulin, Lefamulin may increase the QTc-prolonging activities of Lenvatinib.]
[N04CX01, istradefylline, Istradefylline may decrease the excretion rate of Lenvatinib which could result in a higher serum level.]
[J01XX09, daptomycin, The serum concentration of Lenvatinib can be increased when it is combined with Daptomycin.]
[J01DB01, cephalexin, The excretion of Cephalexin can be decreased when combined with Lenvatinib.]
[J01DB02, cephaloridine, The excretion of Cefaloridine can be decreased when combined with Lenvatinib.]
[N02CC08, lasmiditan, The serum concentration of Lenvatinib can be increased when it is combined with Lasmiditan.]
[N02CD04, ubrogepant, The serum concentration of Ubrogepant can be increased when it is combined with Lenvatinib.]
[L01FX13, enfortumab vedotin, The serum concentration of Enfortumab vedotin can be increased when it is combined with Lenvatinib.]
[R06AB06, dexbrompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Lenvatinib.]
[R06AB02, dexchlorpheniramine, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Dexchlorpheniramine.]
[N05CM21, lemborexant, The serum concentration of Lemborexant can be increased when it is combined with Lenvatinib.]
[L01XX72, tazemetostat, The serum concentration of Tazemetostat can be increased when it is combined with Lenvatinib.]
[N02CD06, rimegepant, The serum concentration of Rimegepant can be increased when it is combined with Lenvatinib.]
[S01AE06, gatifloxacin, The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Lenvatinib.]
[L01EE04, selumetinib, The serum concentration of Selumetinib can be increased when it is combined with Lenvatinib.]
[C01BD07, dronedarone, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Dronedarone.]
[R06AE04, chlorcyclizine, The risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Lenvatinib.]
[L01EH03, tucatinib, Tucatinib may decrease the excretion rate of Lenvatinib which could result in a higher serum level.]
[L01EX17, capmatinib, The serum concentration of Lenvatinib can be increased when it is combined with Capmatinib.]
[L01EX19, ripretinib, Ripretinib may decrease the excretion rate of Lenvatinib which could result in a higher serum level.]
[R02AD04, dyclonine, The risk or severity of methemoglobinemia can be increased when Lenvatinib is combined with Dyclonine.]
[R06AX22, ebastine, The risk or severity of QTc prolongation can be increased when Ebastine is combined with Lenvatinib.]
[J05AX29, fostemsavir, Fostemsavir may decrease the excretion rate of Lenvatinib which could result in a higher serum level.]
[L01FX15, belantamab mafodotin, Lenvatinib may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.]
[P01BA01, chloroquine, The risk or severity of QTc prolongation can be increased when Chloroquine is combined with Lenvatinib.]
[L01EX23, pralsetinib, Pralsetinib may decrease the excretion rate of Lenvatinib which could result in a higher serum level.]
[R06AB04, chlorpheniramine, The risk or severity of QTc prolongation can be increased when Chlorpheniramine is combined with Lenvatinib.]
[N05AA01, chlorpromazine, The risk or severity of QTc prolongation can be increased when Chlorpromazine is combined with Lenvatinib.]
[N05AF03, chlorprothixene, The risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Lenvatinib.]
[V04CK02, cholecystokinin, The excretion of Cholecystokinin can be decreased when combined with Lenvatinib.]
[N02BA03, choline salicylate, The serum concentration of Choline salicylate can be increased when it is combined with Lenvatinib.]
[B06AC06, berotralstat, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Berotralstat.]
[A16AX20, lonafarnib, The serum concentration of Lenvatinib can be increased when it is combined with Lonafarnib.]
[L02BX04, relugolix, The serum concentration of Relugolix can be increased when it is combined with Lenvatinib.]
[L04AD03, voclosporin, The serum concentration of Lenvatinib can be increased when it is combined with Voclosporin.]
[L01EX21, tepotinib, The serum concentration of Lenvatinib can be increased when it is combined with Tepotinib.]
[L01EX25, umbralisib, The serum concentration of Lenvatinib can be increased when it is combined with Umbralisib.]
[V03AF12, trilaciclib, The serum concentration of Trilaciclib can be increased when it is combined with Lenvatinib.]
[N03AX10, felbamate, The risk or severity of QTc prolongation can be increased when Felbamate is combined with Lenvatinib.]
[J01DD15, cefdinir, The excretion of Cefdinir can be decreased when combined with Lenvatinib.]
[J01MB07, flumequine, The risk or severity of QTc prolongation can be increased when Flumequine is combined with Lenvatinib.]
[S01JA01, fluorescein, Lenvatinib may decrease the excretion rate of Fluorescein which could result in a higher serum level.]
[R03CC15, formoterol, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Lenvatinib.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Lenvatinib.]
[L01EK03, tivozanib, Tivozanib may decrease the excretion rate of Lenvatinib which could result in a higher serum level.]
[G03GA06, follitropin beta, The therapeutic efficacy of Follitropin can be decreased when used in combination with Lenvatinib.]
[L01FX22, loncastuximab tesirine, The serum concentration of Loncastuximab tesirine can be increased when it is combined with Lenvatinib.]
[A02BA01, cimetidine, The excretion of Cimetidine can be decreased when combined with Lenvatinib.]
[N07CA02, cinnarizine, The risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Lenvatinib.]
[J01MB06, cinoxacin, The risk or severity of QTc prolongation can be increased when Cinoxacin is combined with Lenvatinib.]
[L01XX73, sotorasib, The serum concentration of Lenvatinib can be increased when it is combined with Sotorasib.]
[S03AA07, ciprofloxacin, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Lenvatinib.]
[L01XA01, cisplatin, The serum concentration of Cisplatin can be increased when it is combined with Lenvatinib.]
[N06AB04, citalopram, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Citalopram.]
[L04AA48, belumosudil, Belumosudil may decrease the excretion rate of Lenvatinib which could result in a higher serum level.]
[P01CA03, fexinidazole, The risk or severity of adverse effects can be increased when Lenvatinib is combined with Fexinidazole.]
[L01EB10, mobocertinib, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Mobocertinib.]
[N02CD07, atogepant, The serum concentration of Atogepant can be increased when it is combined with Lenvatinib.]
[R06AA04, clemastine, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Clemastine.]
[A10BB12, glimepiride, Lenvatinib may decrease the excretion rate of Glimepiride which could result in a higher serum level.]
[L01EA06, asciminib, The serum concentration of Lenvatinib can be increased when it is combined with Asciminib.]
[J05AX10, maribavir, Maribavir may decrease the excretion rate of Lenvatinib which could result in a higher serum level.]
[D11AH08, abrocitinib, The serum concentration of Lenvatinib can be increased when it is combined with Abrocitinib.]
[J04BA01, clofazimine, Clofazimine may decrease the excretion rate of Lenvatinib which could result in a higher serum level.]
[B06AX04, mitapivat, The serum concentration of Lenvatinib can be increased when it is combined with Mitapivat.]
[N01BB10, levobupivacaine, The risk or severity of methemoglobinemia can be increased when Lenvatinib is combined with Levobupivacaine.]
[L01EJ03, pacritinib, The serum concentration of Lenvatinib can be increased when it is combined with Pacritinib.]
[G03GB02, clomiphene, The serum concentration of Lenvatinib can be increased when it is combined with Clomifene.]
[N06AA04, clomipramine, The risk or severity of QTc prolongation can be increased when Clomipramine is combined with Lenvatinib.]
[J05AB17, brincidofovir, The serum concentration of Brincidofovir can be increased when it is combined with Lenvatinib.]
[J05AH02, oseltamivir, The excretion of Oseltamivir can be decreased when combined with Lenvatinib.]
[J02AC06, oteseconazole, The serum concentration of Lenvatinib can be increased when it is combined with Oteseconazole.]
[A05BA08, glycyrrhizic acid, Lenvatinib may decrease the excretion rate of Glycyrrhizic acid which could result in a higher serum level.]
[A04AA01, ondansetron, The risk or severity of QTc prolongation can be increased when Ondansetron is combined with Lenvatinib.]
[A04AA02, granisetron, The risk or severity of QTc prolongation can be increased when Granisetron is combined with Lenvatinib.]
[N05AH02, clozapine, The risk or severity of QTc prolongation can be increased when Clozapine is combined with Lenvatinib.]
[L01EN04, futibatinib, The serum concentration of Futibatinib can be increased when it is combined with Lenvatinib.]
[A10BK06, sotagliflozin, Sotagliflozin may decrease the excretion rate of Lenvatinib which could result in a higher serum level.]
[S02DA02, cocaine, The risk or severity of methemoglobinemia can be increased when Lenvatinib is combined with Cocaine.]
[M04AC01, colchicine, The serum concentration of Lenvatinib can be increased when it is combined with Colchicine.]
[N01AB07, desflurane, The risk or severity of QTc prolongation can be increased when Desflurane is combined with Lenvatinib.]
[J01FA15, telithromycin, The risk or severity of QTc prolongation can be increased when Telithromycin is combined with Lenvatinib.]
[R06AX27, desloratadine, The risk or severity of QTc prolongation can be increased when Desloratadine is combined with Lenvatinib.]
[J02AC02, itraconazole, Itraconazole may decrease the excretion rate of Lenvatinib which could result in a higher serum level.]
[S01AD03, acyclovir, The excretion of Acyclovir can be decreased when combined with Lenvatinib.]
[S01GX06, emedastine, The risk or severity of QTc prolongation can be increased when Emedastine is combined with Lenvatinib.]
[L01EA01, imatinib, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Imatinib.]
[J02AC04, posaconazole, The serum concentration of Lenvatinib can be increased when it is combined with Posaconazole.]
[C08CA09, lacidipine, The risk or severity of QTc prolongation can be increased when Lacidipine is combined with Lenvatinib.]
[B03XA02, darbepoetin alfa, The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Lenvatinib.]
[N03AX09, lamotrigine, The risk or severity of QTc prolongation can be increased when Lamotrigine is combined with Lenvatinib.]
[S01GX02, levocabastine, The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Lenvatinib.]
[N07BC04, lofexidine, The risk or severity of QTc prolongation can be increased when Lofexidine is combined with Lenvatinib.]
[S01AE04, lomefloxacin, The risk or severity of QTc prolongation can be increased when Lomefloxacin is combined with Lenvatinib.]
[R06AX13, loratadine, Lenvatinib may decrease the excretion rate of Loratadine which could result in a higher serum level.]
[R06AD07, mequitazine, The risk or severity of QTc prolongation can be increased when Mequitazine is combined with Lenvatinib.]
[C01EB10, adenosine, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Lenvatinib.]
[R06AE03, cyclizine, The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Lenvatinib.]
[N05AD03, metylperon, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Melperone.]
[J05AF07, tenofovir disoproxil, The excretion of Tenofovir disoproxil can be decreased when combined with Lenvatinib.]
[S01XA18, cyclosporine, Cyclosporine may decrease the excretion rate of Lenvatinib which could result in a higher serum level.]
[R06AX02, cyproheptadine, The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Lenvatinib.]
[C09AA13, moexipril, The risk or severity of QTc prolongation can be increased when Moexipril is combined with Lenvatinib.]
[C10AA07, rosuvastatin, Lenvatinib may decrease the excretion rate of Rosuvastatin which could result in a higher serum level.]
[C03XA02, conivaptan, The serum concentration of Lenvatinib can be increased when it is combined with Conivaptan.]
[G04BE09, vardenafil, The serum concentration of Lenvatinib can be increased when it is combined with Vardenafil.]
[L01DA01, dactinomycin, The serum concentration of Dactinomycin can be increased when it is combined with Lenvatinib.]
[L01DB02, daunorubicin, Lenvatinib may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[N06AX06, nefazodone, Lenvatinib may decrease the excretion rate of Nefazodone which could result in a higher serum level.]
[N06AB10, escitalopram, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Escitalopram.]
[G04BD08, solifenacin, The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Lenvatinib.]
[N06AA01, desipramine, The risk or severity of QTc prolongation can be increased when Desipramine is combined with Lenvatinib.]
[L01XA03, oxaliplatin, The serum concentration of Oxaliplatin can be increased when it is combined with Lenvatinib.]
[S03BA01, dexamethasone, The excretion of Dexamethasone can be decreased when combined with Lenvatinib.]
[L01EB01, gefitinib, Gefitinib may decrease the excretion rate of Lenvatinib which could result in a higher serum level.]
[H05AA02, teriparatide, The therapeutic efficacy of Teriparatide can be decreased when used in combination with Lenvatinib.]
[R02AA19, phenol, The risk or severity of methemoglobinemia can be increased when Lenvatinib is combined with Phenol.]
[S02DA04, dibucaine, The risk or severity of methemoglobinemia can be increased when Lenvatinib is combined with Cinchocaine.]
[S01BC03, diclofenac, Lenvatinib may decrease the excretion rate of Diclofenac which could result in a higher serum level.]
[J05AD01, foscarnet, The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Lenvatinib.]
[J05AF03, zalcitabine, The excretion of Zalcitabine can be decreased when combined with Lenvatinib.]
[J05AF02, didanosine, The excretion of Didanosine can be decreased when combined with Lenvatinib.]
[A03AX04, pinaverium, The risk or severity of QTc prolongation can be increased when Pinaverium is combined with Lenvatinib.]
[L01DC04, ixabepilone, The serum concentration of Lenvatinib can be increased when it is combined with Ixabepilone.]
[L01EB02, erlotinib, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Erlotinib.]
[L02AA01, diethylstilbestrol, Lenvatinib may decrease the excretion rate of Diethylstilbestrol which could result in a higher serum level.]
[C08CA03, isradipine, Lenvatinib may decrease the excretion rate of Isradipine which could result in a higher serum level.]
[C01AA04, digitoxin, The serum concentration of Digitoxin can be increased when it is combined with Lenvatinib.]
[C01AA05, digoxin, Lenvatinib may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C10AX09, ezetimibe, Lenvatinib may decrease the excretion rate of Ezetimibe which could result in a higher serum level.]
[C04AE04, dihydroergocristine, Lenvatinib may decrease the excretion rate of Dihydroergocristine which could result in a higher serum level.]
[J05AE08, atazanavir, Lenvatinib may decrease the excretion rate of Atazanavir which could result in a higher serum level.]
[B01AC21, treprostinil, The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Lenvatinib.]
[H03BC01, potassium perchlorate, The therapeutic efficacy of Potassium perchlorate can be decreased when used in combination with Lenvatinib.]
[D04AB07, pramoxine, The risk or severity of methemoglobinemia can be increased when Lenvatinib is combined with Pramocaine.]
[C08DB01, diltiazem, The risk or severity of QTc prolongation can be increased when Diltiazem is combined with Lenvatinib.]
[R06AA11, dimenhydrinate, The risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Lenvatinib.]
[G02AD02, dinoprostone, The excretion of Dinoprostone can be decreased when combined with Lenvatinib.]
[C05CA03, diosmin, The serum concentration of Lenvatinib can be increased when it is combined with Diosmin.]
[S01HA04, proparacaine, The risk or severity of methemoglobinemia can be increased when Lenvatinib is combined with Proparacaine.]
[R06AA02, diphenhydramine, The risk or severity of methemoglobinemia can be increased when Lenvatinib is combined with Diphenhydramine.]
[C09AA06, quinapril, The excretion of Quinapril can be decreased when combined with Lenvatinib.]
[B01AC07, dipyridamole, Lenvatinib may decrease the excretion rate of Dipyridamole which could result in a higher serum level.]
[A03FA02, cisapride, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Cisapride.]
[S01XA23, sirolimus, The serum concentration of Sirolimus can be increased when it is combined with Lenvatinib.]
[C01BA03, disopyramide, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Disopyramide.]
[P03AA04, disulfiram, Lenvatinib may decrease the excretion rate of Disulfiram which could result in a higher serum level.]
[S02AA12, rifamycin SV, The serum concentration of Lenvatinib can be increased when it is combined with Rifamycin.]
[N05AX08, risperidone, The risk or severity of QTc prolongation can be increased when Risperidone is combined with Lenvatinib.]
[R06AE09, levocetirizine, The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Lenvatinib.]
[N01BB09, ropivacaine, The risk or severity of methemoglobinemia can be increased when Lenvatinib is combined with Ropivacaine.]
[J01MB01, rosoxacin, The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Lenvatinib.]
[L01EX01, sunitinib, Sunitinib may decrease the excretion rate of Lenvatinib which could result in a higher serum level.]
[C03XA01, tolvaptan, The serum concentration of Tolvaptan can be increased when it is combined with Lenvatinib.]
[L01XG01, bortezomib, The serum concentration of Bortezomib can be increased when it is combined with Lenvatinib.]
[C02KX02, ambrisentan, The serum concentration of Lenvatinib can be increased when it is combined with Ambrisentan.]
[C01EB18, ranolazine, The serum concentration of Lenvatinib can be increased when it is combined with Ranolazine.]
[R03AC12, salmeterol, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Lenvatinib.]
[H05BA01, salmon calcitonin, The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Lenvatinib.]
[A03FA03, domperidone, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Domperidone.]
[C01CA04, dopamine, The serum concentration of Dopamine can be increased when it is combined with Lenvatinib.]
[N06AA16, dothiepin, The risk or severity of QTc prolongation can be increased when Dosulepin is combined with Lenvatinib.]
[N06AA12, doxepin, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Lenvatinib.]
[L01DB01, doxorubicin, Lenvatinib may decrease the excretion rate of Doxorubicin which could result in a higher serum level.]
[R06AA09, doxylamine, The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Lenvatinib.]
[N01AB08, sevoflurane, The risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Lenvatinib.]
[N05AD08, droperidol, The risk or severity of QTc prolongation can be increased when Droperidol is combined with Lenvatinib.]
[C10AA01, simvastatin, Lenvatinib may decrease the excretion rate of Simvastatin which could result in a higher serum level.]
[N05AL02, sultopride, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Sultopride.]
[N02CC01, sumatriptan, The excretion of Sumatriptan can be decreased when combined with Lenvatinib.]
[C07AB13, talinolol, The serum concentration of Talinolol can be increased when it is combined with Lenvatinib.]
[J01CG02, tazobactam, The excretion of Tazobactam can be decreased when combined with Lenvatinib.]
[J01MA05, temafloxacin, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Temafloxacin.]
[G04BD05, terodiline, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Terodiline.]
[C09AA02, enalapril, The excretion of Enalapril can be decreased when combined with Lenvatinib.]
[N06BA09, atomoxetine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Lenvatinib.]
[L02BA02, toremifene, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Toremifene.]
[C03CA04, torsemide, The excretion of Torasemide can be decreased when combined with Lenvatinib.]
[G03GA05, follitropin alfa, The therapeutic efficacy of Follitropin can be decreased when used in combination with Lenvatinib.]
[L02AE04, triptorelin, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Lenvatinib.]
[J01MA04, enoxacin, The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Lenvatinib.]
[S01GX10, epinastine, The risk or severity of QTc prolongation can be increased when Epinastine is combined with Lenvatinib.]
[N06AX16, venlafaxine, Venlafaxine may increase the excretion rate of Lenvatinib which could result in a lower serum level and potentially a reduction in efficacy.]
[S01EA01, epinephrine, The serum concentration of Epinephrine can be increased when it is combined with Lenvatinib.]
[N03AX15, zonisamide, The serum concentration of Lenvatinib can be increased when it is combined with Zonisamide.]
[C01BG01, moricizine, The risk or severity of QTc prolongation can be increased when Moricizine is combined with Lenvatinib.]
[S01AA17, erythromycin, Lenvatinib may decrease the excretion rate of Erythromycin which could result in a higher serum level.]
[A02BC02, pantoprazole, Pantoprazole may decrease the excretion rate of Lenvatinib which could result in a higher serum level.]
[G03CA03, estradiol, The excretion of Estradiol can be decreased when combined with Lenvatinib.]
[G03CA57, estrogens, conjugated (USP), The excretion of Conjugated estrogens can be decreased when combined with Lenvatinib.]
[C10AA04, fluvastatin, The excretion of Fluvastatin can be decreased when combined with Lenvatinib.]
[L02AA03, ethinyl estradiol, The risk or severity of liver damage can be increased when Ethinylestradiol is combined with Lenvatinib.]
[C01BD05, ibutilide, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Ibutilide.]
[N03AD01, ethosuximide, The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Lenvatinib.]
[N01BX01, ethyl chloride, The risk or severity of methemoglobinemia can be increased when Lenvatinib is combined with Ethyl chloride.]
[M01AC06, meloxicam, The risk or severity of methemoglobinemia can be increased when Lenvatinib is combined with Meloxicam.]
[N01BB07, etidocaine, The risk or severity of methemoglobinemia can be increased when Lenvatinib is combined with Etidocaine.]
[L01CB01, etoposide, The serum concentration of Etoposide can be increased when it is combined with Lenvatinib.]
[C01BA05, ajmaline, The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Lenvatinib.]
[L04AD02, tacrolimus, The serum concentration of Lenvatinib can be increased when it is combined with Tacrolimus.]
[J01MA08, fleroxacin, The risk or severity of QTc prolongation can be increased when Fleroxacin is combined with Lenvatinib.]
[R06AX11, astemizole, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Astemizole.]
[R06AX12, terfenadine, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Terfenadine.]
[N06AB08, fluvoxamine, Lenvatinib may decrease the excretion rate of Fluvoxamine which could result in a higher serum level.]
[C01BC08, encainide, The risk or severity of QTc prolongation can be increased when Encainide is combined with Lenvatinib.]
[L02AE02, leuprolide, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Lenvatinib.]
[C10AA03, pravastatin, Lenvatinib may decrease the excretion rate of Pravastatin which could result in a higher serum level.]
[A02BA03, famotidine, The excretion of Famotidine can be decreased when combined with Lenvatinib.]
[A16AA01, levocarnitine, The excretion of Levocarnitine can be decreased when combined with Lenvatinib.]
[C08CA02, felodipine, Lenvatinib may decrease the excretion rate of Felodipine which could result in a higher serum level.]
[C08EA01, fendiline, The risk or severity of QTc prolongation can be increased when Fendiline is combined with Lenvatinib.]
[R03CC02, albuterol, The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Lenvatinib.]
[L01BB06, clofarabine, The serum concentration of Clofarabine can be increased when it is combined with Lenvatinib.]
[C01BC04, flecainide, The risk or severity of QTc prolongation can be increased when Flecainide is combined with Lenvatinib.]
[J01CF05, floxacillin, Lenvatinib may decrease the excretion rate of Flucloxacillin which could result in a higher serum level.]
[J02AC01, fluconazole, The serum concentration of Lenvatinib can be increased when it is combined with Fluconazole.]
[L01BC02, fluorouracil, The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Lenvatinib.]
[N06AB03, fluoxetine, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Lenvatinib.]
[N05AF01, flupenthixol, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Flupentixol.]
[N05AG01, fluspirilene, The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Lenvatinib.]
[J05AE10, darunavir, The serum concentration of Lenvatinib can be increased when it is combined with Darunavir.]
[N05AL05, amisulpride, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Amisulpride.]
[N06DA04, galantamine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Lenvatinib.]
[C08DA02, gallopamil, The risk or severity of QTc prolongation can be increased when Gallopamil is combined with Lenvatinib.]
[J01XA03, telavancin, The risk or severity of QTc prolongation can be increased when Telavancin is combined with Lenvatinib.]
[L02BX02, degarelix, The risk or severity of QTc prolongation can be increased when Degarelix is combined with Lenvatinib.]
[L01EA02, dasatinib, Dasatinib may decrease the excretion rate of Lenvatinib which could result in a higher serum level.]
[N04BC06, cabergoline, The serum concentration of Cabergoline can be increased when it is combined with Lenvatinib.]
[N03AD03, methsuximide, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Lenvatinib.]
[L01EH01, lapatinib, The serum concentration of Lenvatinib can be increased when it is combined with Lapatinib.]
[A10BB01, glyburide, Lenvatinib may decrease the excretion rate of Glyburide which could result in a higher serum level.]
[A10BB07, glipizide, Lenvatinib may decrease the excretion rate of Glipizide which could result in a higher serum level.]
[C01BD04, dofetilide, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Dofetilide.]
[H01AB01, thyrotropin alfa, The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Lenvatinib.]
[L01EX02, sorafenib, Sorafenib may decrease the excretion rate of Lenvatinib which could result in a higher serum level.]
[C07AB09, esmolol, The risk or severity of QTc prolongation can be increased when Esmolol is combined with Lenvatinib.]
[L02AE03, goserelin, The risk or severity of QTc prolongation can be increased when Goserelin is combined with Lenvatinib.]
[P01BX01, halofantrine, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Halofantrine.]
[N05AD01, haloperidol, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Haloperidol.]
[L02AE05, histrelin, The risk or severity of QTc prolongation can be increased when Histrelin is combined with Lenvatinib.]
[N05AH04, quetiapine, The risk or severity of QTc prolongation can be increased when Quetiapine is combined with Lenvatinib.]
[M04AA01, allopurinol, The excretion of Allopurinol can be decreased when combined with Lenvatinib.]
[C09CA01, losartan, Lenvatinib may decrease the excretion rate of Losartan which could result in a higher serum level.]
[A07EC02, mesalamine, The excretion of Mesalazine can be decreased when combined with Lenvatinib.]
[C08CA10, nilvadipine, The risk or severity of QTc prolongation can be increased when Nilvadipine is combined with Lenvatinib.]
[R06AE06, oxatomide, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Oxatomide.]
[C03AA03, hydrochlorothiazide, The excretion of Hydrochlorothiazide can be decreased when combined with Lenvatinib.]
[S02BA01, hydrocortisone, The excretion of Hydrocortisone can be decreased when combined with Lenvatinib.]
[P01BA02, hydroxychloroquine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Lenvatinib.]
[N05BB01, hydroxyzine, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Hydroxyzine.]
[N06AA02, imipramine, The risk or severity of QTc prolongation can be increased when Imipramine is combined with Lenvatinib.]
[L01CD01, paclitaxel, Lenvatinib may decrease the excretion rate of Paclitaxel which could result in a higher serum level.]
[H01BA04, terlipressin, The risk or severity of QTc prolongation can be increased when Terlipressin is combined with Lenvatinib.]
[M03BX02, tizanidine, The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Lenvatinib.]
[L01CE01, topotecan, The serum concentration of Topotecan can be increased when it is combined with Lenvatinib.]
[C03BA11, indapamide, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Lenvatinib.]
[S01BC01, indomethacin, Lenvatinib may decrease the excretion rate of Indomethacin which could result in a higher serum level.]
[S01XA28, varenicline, The excretion of Varenicline can be decreased when combined with Lenvatinib.]
[N01BB08, articaine, The risk or severity of methemoglobinemia can be increased when Lenvatinib is combined with Articaine.]
[A10BH01, sitagliptin, The excretion of Sitagliptin can be decreased when combined with Lenvatinib.]
[R06AE01, buclizine, The risk or severity of QTc prolongation can be increased when Buclizine is combined with Lenvatinib.]
[C10AA06, cerivastatin, Lenvatinib may decrease the excretion rate of Cerivastatin which could result in a higher serum level.]
[L01XX35, anagrelide, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Anagrelide.]
[J05AF04, stavudine, The excretion of Stavudine can be decreased when combined with Lenvatinib.]
[G04BE01, alprostadil, The excretion of Alprostadil can be decreased when combined with Lenvatinib.]
[N01AB06, isoflurane, The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Lenvatinib.]
[J02AB02, ketoconazole, Lenvatinib may decrease the excretion rate of Ketoconazole which could result in a higher serum level.]
[H02CA04, levoketoconazole, The serum concentration of Lenvatinib can be increased when it is combined with Levoketoconazole.]
[N05AH03, olanzapine, The risk or severity of QTc prolongation can be increased when Olanzapine is combined with Lenvatinib.]
[R06AX25, mizolastine, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Mizolastine.]
[J01MB02, nalidixic acid, The risk or severity of QTc prolongation can be increased when Nalidixic acid is combined with Lenvatinib.]
[N04BB01, amantadine, The serum concentration of Amantadine can be increased when it is combined with Lenvatinib.]
[S02DA01, lidocaine, The risk or severity of methemoglobinemia can be increased when Lenvatinib is combined with Lidocaine.]
[C08EX01, lidoflazine, The risk or severity of QTc prolongation can be increased when Lidoflazine is combined with Lenvatinib.]
[A07DA03, loperamide, The risk or severity of QTc prolongation can be increased when Loperamide is combined with Lenvatinib.]
[C10AA02, lovastatin, Lenvatinib may decrease the excretion rate of Lovastatin which could result in a higher serum level.]
[N05AH01, loxapine, The serum concentration of Lenvatinib can be increased when it is combined with Loxapine.]
[L01EG01, temsirolimus, The serum concentration of Lenvatinib can be increased when it is combined with Temsirolimus.]
[L01EA03, nilotinib, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Nilotinib.]
[V04CX04, mannitol, The serum concentration of Lenvatinib can be increased when it is combined with Mannitol.]
[N06AA21, maprotiline, The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Lenvatinib.]
[P01BC02, mefloquine, The serum concentration of Lenvatinib can be increased when it is combined with Mefloquine.]
[N06DX01, memantine, The serum concentration of Memantine can be increased when it is combined with Lenvatinib.]
[N01BB03, mepivacaine, The risk or severity of methemoglobinemia can be increased when Lenvatinib is combined with Mepivacaine.]
[N05AC03, mesoridazine, The risk or severity of QTc prolongation can be increased when Mesoridazine is combined with Lenvatinib.]
[N05AX13, paliperidone, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Paliperidone.]
[A10BA02, metformin, The serum concentration of Metformin can be increased when it is combined with Lenvatinib.]
[A04AA04, dolasetron, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Lenvatinib.]
[N07BC02, methadone, The risk or severity of QTc prolongation can be increased when Methadone is combined with Lenvatinib.]
[J05AF05, lamivudine, The serum concentration of Lamivudine can be increased when it is combined with Lenvatinib.]
[H03BB02, methimazole, The therapeutic efficacy of Methimazole can be decreased when used in combination with Lenvatinib.]
[L01BA04, pemetrexed, Lenvatinib may decrease the excretion rate of Pemetrexed which could result in a higher serum level.]
[L04AX03, methotrexate, The excretion of Methotrexate can be decreased when combined with Lenvatinib.]
[N05AA02, methotrimeprazine, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Lenvatinib.]
[V04CG05, methylene blue, The serum concentration of Lenvatinib can be increased when it is combined with Methylene blue.]
[A03FA01, metoclopramide, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Lenvatinib.]
[P01AB01, metronidazole, The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Lenvatinib.]
[G03XB01, mifepristone, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Mifepristone.]
[C09CA03, valsartan, The excretion of Valsartan can be decreased when combined with Lenvatinib.]
[C01BD01, amiodarone, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Amiodarone.]
[N06AA09, amitriptyline, The risk or severity of QTc prolongation can be increased when Amitriptyline is combined with Lenvatinib.]
[N02AA01, morphine, The serum concentration of Lenvatinib can be increased when it is combined with Morphine.]
[B02BX05, eltrombopag, Eltrombopag may decrease the excretion rate of Lenvatinib which could result in a higher serum level.]
[L01EX03, pazopanib, The risk or severity of QTc prolongation can be increased when Pazopanib is combined with Lenvatinib.]
[P01BA06, amodiaquine, The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Lenvatinib.]
[G04CA04, silodosin, The serum concentration of Lenvatinib can be increased when it is combined with Silodosin.]
[G03XC01, raloxifene, The excretion of Raloxifene can be decreased when combined with Lenvatinib.]
[N06AA17, amoxapine, The risk or severity of QTc prolongation can be increased when Amoxapine is combined with Lenvatinib.]
[M02AA12, naproxen, Lenvatinib may decrease the excretion rate of Naproxen which could result in a higher serum level.]
[A10BG01, troglitazone, The risk or severity of liver damage can be increased when Troglitazone is combined with Lenvatinib.]
[B03XA03, methoxy polyethylene glycol-epoetin beta, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Lenvatinib.]
[A10BX02, repaglinide, Lenvatinib may decrease the excretion rate of Repaglinide which could result in a higher serum level.]
[C01CX08, levosimendan, The risk or severity of QTc prolongation can be increased when Levosimendan is combined with Lenvatinib.]
[N05AX14, iloperidone, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Iloperidone.]
[C09CA07, telmisartan, Lenvatinib may decrease the excretion rate of Telmisartan which could result in a higher serum level.]
[J05AB11, valacyclovir, The excretion of Valaciclovir can be decreased when combined with Lenvatinib.]
[M04AA03, febuxostat, The excretion of Lenvatinib can be decreased when combined with Febuxostat.]
[C08CA04, nicardipine, Lenvatinib may decrease the excretion rate of Nicardipine which could result in a higher serum level.]
[C08CA05, nifedipine, Lenvatinib may decrease the excretion rate of Nifedipine which could result in a higher serum level.]
[C08CA06, nimodipine, The risk or severity of QTc prolongation can be increased when Nimodipine is combined with Lenvatinib.]
[C08CA08, nitrendipine, Lenvatinib may decrease the excretion rate of Nitrendipine which could result in a higher serum level.]
[J01XE01, nitrofurantoin, Lenvatinib may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.]
[N04BC05, pramipexole, The serum concentration of Pramipexole can be increased when it is combined with Lenvatinib.]
[C01CA03, norepinephrine, The serum concentration of Norepinephrine can be increased when it is combined with Lenvatinib.]
[S01AE02, norfloxacin, The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Lenvatinib.]
[C02KX01, bosentan, The risk or severity of liver damage can be increased when Bosentan is combined with Lenvatinib.]
[N06AA10, nortriptyline, The serum concentration of Nortriptyline can be increased when it is combined with Lenvatinib.]
[A16AX07, sapropterin, The serum concentration of Lenvatinib can be increased when it is combined with Sapropterin.]
[H01CB02, octreotide, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Lenvatinib.]
[S02AA16, ofloxacin, Lenvatinib may decrease the excretion rate of Ofloxacin which could result in a higher serum level.]
[A02BC01, omeprazole, Omeprazole may decrease the excretion rate of Lenvatinib which could result in a higher serum level.]
[C01AC01, ouabain, The excretion of Ouabain can be decreased when combined with Lenvatinib.]
[J01MB05, oxolinic acid, The risk or severity of QTc prolongation can be increased when Oxolinic acid is combined with Lenvatinib.]
[S01AA04, oxytetracycline, The excretion of Oxytetracycline can be decreased when combined with Lenvatinib.]
[H01BB02, oxytocin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Lenvatinib.]
[V04CH30, 4-aminohippuric acid, The excretion of Aminohippuric acid can be decreased when combined with Lenvatinib.]
[N05AH05, asenapine, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Asenapine.]
[G04BE02, papaverine, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Lenvatinib.]
[J01MA03, pefloxacin, The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Lenvatinib.]
[N05AG03, penfluridol, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Penfluridol.]
[M01CC01, penicillamine, The excretion of Penicillamine can be decreased when combined with Lenvatinib.]
[S01AA14, penicillin G, The excretion of Benzylpenicillin can be decreased when combined with Lenvatinib.]
[C08EX02, perhexiline, The risk or severity of QTc prolongation can be increased when Perhexiline is combined with Lenvatinib.]
[R06AB05, pheniramine, The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Lenvatinib.]
[S01AE05, levofloxacin, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Lenvatinib.]
[N07BB03, acamprosate, The excretion of Acamprosate can be decreased when combined with Lenvatinib.]
[J05AB12, cidofovir, The excretion of Cidofovir can be decreased when combined with Lenvatinib.]
[C08CX01, mibefradil, The risk or severity of QTc prolongation can be increased when Mibefradil is combined with Lenvatinib.]
[N05AG02, pimozide, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Pimozide.]
[C10AA05, atorvastatin, Lenvatinib may decrease the excretion rate of Atorvastatin which could result in a higher serum level.]
[J01CA12, piperacillin, The excretion of Piperacillin can be decreased when combined with Lenvatinib.]
[J05AE01, saquinavir, Lenvatinib may decrease the excretion rate of Saquinavir which could result in a higher serum level.]
[J01MA11, grepafloxacin, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Grepafloxacin.]
[A10BG02, rosiglitazone, Lenvatinib may decrease the excretion rate of Rosiglitazone which could result in a higher serum level.]
[C03AA05, polythiazide, The excretion of Polythiazide can be decreased when combined with Lenvatinib.]
[J05AE03, ritonavir, Lenvatinib may decrease the excretion rate of Ritonavir which could result in a higher serum level.]
[A10BH03, saxagliptin, The excretion of Saxagliptin can be decreased when combined with Lenvatinib.]
[V03AB21, potassium iodide, The therapeutic efficacy of Potassium Iodide can be decreased when used in combination with Lenvatinib.]
[C10AA08, pitavastatin, Lenvatinib may decrease the excretion rate of Pitavastatin which could result in a higher serum level.]
[C01BA08, prajmaline, The risk or severity of QTc prolongation can be increased when Prajmaline is combined with Lenvatinib.]
[C02CA01, prazosin, The serum concentration of Prazosin can be increased when it is combined with Lenvatinib.]
[R06AX05, antazoline, The risk or severity of QTc prolongation can be increased when Antazoline is combined with Lenvatinib.]
[C01DX02, prenylamine, The risk or severity of QTc prolongation can be increased when Prenylamine is combined with Lenvatinib.]
[N01BB04, prilocaine, The risk or severity of methemoglobinemia can be increased when Lenvatinib is combined with Prilocaine.]
[P01BA03, primaquine, The risk or severity of QTc prolongation can be increased when Primaquine is combined with Lenvatinib.]
[C10AX02, probucol, The risk or severity of QTc prolongation can be increased when Probucol is combined with Lenvatinib.]
[C01BA02, procainamide, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Procainamide.]
[S01HA05, procaine, The risk or severity of methemoglobinemia can be increased when Lenvatinib is combined with Procaine.]
[C10AB05, fenofibrate, Lenvatinib may decrease the excretion rate of Fenofibrate which could result in a higher serum level.]
[N05AB04, prochlorperazine, The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Lenvatinib.]
[G03DA04, progesterone, Progesterone may decrease the excretion rate of Lenvatinib which could result in a higher serum level.]
[N05AA03, promazine, The risk or severity of QTc prolongation can be increased when Promazine is combined with Lenvatinib.]
[R06AD02, promethazine, The risk or severity of QTc prolongation can be increased when Promethazine is combined with Lenvatinib.]
[C01BC03, propafenone, The risk or severity of QTc prolongation can be increased when Propafenone is combined with Lenvatinib.]
[R06AX26, fexofenadine, The excretion of Fexofenadine can be decreased when combined with Lenvatinib.]
[L01XH02, romidepsin, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Romidepsin.]
[N01AX10, propofol, The risk or severity of QTc prolongation can be increased when Propofol is combined with Lenvatinib.]
[H03BA02, propylthiouracil, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Lenvatinib.]
[N06AA11, protriptyline, The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Lenvatinib.]
[N05AX12, aripiprazole, The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Lenvatinib.]
[N07XX07, dalfampridine, The serum concentration of Dalfampridine can be increased when it is combined with Lenvatinib.]
[R06AC01, pyrilamine, The risk or severity of QTc prolongation can be increased when Mepyramine is combined with Lenvatinib.]
[C01BA01, quinidine, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Quinidine.]
[P01BC01, quinine, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Quinine.]
[A02BA02, ranitidine, The excretion of Ranitidine can be decreased when combined with Lenvatinib.]
[C02AA02, reserpine, The serum concentration of Lenvatinib can be increased when it is combined with Reserpine.]
[J04AB02, rifampin, The risk or severity of liver damage can be increased when Rifampicin is combined with Lenvatinib.]
[J01FA06, roxithromycin, The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Lenvatinib.]
[A07EC01, sulfasalazine, Sulfasalazine may decrease the excretion rate of Lenvatinib which could result in a higher serum level.]
[C07AA07, sotalol, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Sotalol.]
[L01CD04, cabazitaxel, Cabazitaxel may decrease the excretion rate of Lenvatinib which could result in a higher serum level.]
[C03DA01, spironolactone, Lenvatinib may decrease the excretion rate of Spironolactone which could result in a higher serum level.]
[J05AF08, adefovir dipivoxil, The excretion of Adefovir dipivoxil can be decreased when combined with Lenvatinib.]
[L01FD03, ado-trastuzumab emtansine, The serum concentration of Trastuzumab emtansine can be increased when it is combined with Lenvatinib.]
[V09GA01, technetium Tc 99m sestamibi, The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Lenvatinib.]
[N03AG01, valproic acid, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Valproic acid.]
[A05AA02, ursodiol, Lenvatinib may decrease the excretion rate of Ursodeoxycholic acid which could result in a higher serum level.]
